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ORIGINAL RESEARCH
Abstract: This paper examines the role of selective serotonin reuptake inhibitors (SSRIs) in
the treatment of hepatitis-C virus (HCV) patients who have developed interferon-α induced
depression. A 2-year data analysis of HCV psychiatric liaison clinic has been undertaken.
The diagnosis, treatment, and progress of those patients who were treated with interferon-α
(INF-α) are reported. 53 of the 78 patients enrolled at the HCV Clinic and treated with INF-
α were referred for psychiatric consultation. Six patients developed major depressive illness
following INF therapy. They were all treated with SSRIs and they made full recovery. This is
a significant observation and is concordant with other studies. Its biochemical ramifications
are presented. It is concluded that INF-induced depression is fully reversible. A hypothesis is
proposed that SSRIs modulate the neuro-protective neurotoxic ratio by possibly inhibiting
the indole-2,3-dioxygenase induction of the kynurenine pathway.
Keywords: hepatitis-C virus (HCV), SSRIs, interferon-α, indole-2,3-dioxygenase, major
depression
Introduction
Hepatitis C is a major public health problem, 170 million people were reported to be
affected worldwide (WHO 1999), 225 000 in Australia (2002). The cytokine interferon
alpha (INF-α) is administered in the treatment of hepatitis-C virus infection (HCV)
for its immuno-protective quality. The HCV is an enveloped RNA virus and 50% of
infections progress to chronicity and up to 70% of the asymptomatic carriers have
chronic active hepatitis and or cirrhosis. HCV produces symptoms of major depression
including fatigue, increased sleepiness, irritability, loss of appetite, and cognitive
difficulties (Capuron et al 2001; Wichers and Maes 2002; Wichers et al 2005a). It
has been hypothesized that major depressive illness in the general population is
accompanied by activation of the inflammatory response system. An increased
production and levels of pro-inflammatory cytokines by monocytes and Th-1 like
lymphocytes, for example, interlukin-1β, IL-6, tumour necrosis factor-α (TNF-α),
and INF-γ (Kronfol 2002), have been found in major depression occurring in the
general population. Pro-inflammatory cytokines have been found to have significant
effects on the tryptophan metabolism through the enzyme indoleamine-2,3-
dioxygenase (IDO), which is activated. This results in diversion of tryptophan causing
an increase in the ratio of neuro-protective kynurenate and neurotoxic–
neurodegenerative quinolinate (Myint and Kim 2003). This cytokine–tryptophan
interaction leading to an imbalance between quinolinate and kynnurate in the brain
lies at the basis of the neurodegerative hypothesis of depression. In INF-α-induced
depression intervention with selective serotonin reuptake inhibitors (SSRIs)
ameliorates the symptoms (Mussulman et al 2001). This paper concerns the onset of
major depression in a cohort of INF-α-induced depression in HCV patients and the
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clinical observation of complete recovery with SSRIs.
Activity of IDO as the possible cause of IFN-α-induced
depression is also discussed.
Methodology
We examined the role of SSRI antidepressant therapy in
INF-α-induced depression in patients with HCV. The data
were collected from the psychiatric liaison liver clinic of a
large teaching hospital in Canberra. Treating specialists and
nursing staff referred patients requiring psychiatric input.
No formal screening tools were applied prior to psychiatric
consultation. The main reasons for referrals were 1)
identifying high risk cases to determine the suitability for
combination INF-α and ribavirin treatment; 2) developing
a comprehensive treatment plan with the liver clinic team
in selected cases to maximize compliance for completion
of therapy; and 3) for early detection and treatment of INF-
α-induced neuropsychiatric complications particularly
depression in order to achieve better treatment outcome.
All patients were enrolled for HCV treatment as per the
liver clinic protocol. A consultant psychiatrist examined the
referred patients and the psychiatric diagnoses were based
on the DSM-IV criteria. Treatment outcome was measured
as an achievement of remission symptoms of major
depression.
Results
A total of 78 patients were assessed and found eligible for
INF-α treatment by the gastroenterology team in their Hep
C clinic. Of these, 53 patients were referred for psychiatric
consultation. The mean age of the cohort was 40 years and
males represented 62.8% of the sample. The mean duration
of HCV was 11.79 years. Five of these patients developed
an aggravation of personality disorder NOS (DSM-IV)
without co-morbid depression. One patient developed severe
neurotoxicity and another one developed psychosis. Six of
the 53 patients developed major depressive illness following
the INF-α treatment and had no other psychiatric co-
morbidity. Six patients who developed major depression and
5 who had aggravation of personality disorder were treated
with SSRI antidepressants and their progress was recorded
fortnightly. All the six patients who developed depression
after the INF- treatment achieved full remission. Four of
these patients completed the full course of INF and ribavirin
treatment for a period of 6–12 months, 1 patient developed
liver cell carcinoma, and 1 dropped out in spite of good
remission before completing the antiviral therapy. Table 1
provides more details of these six patients. The five patients
who had aggravation of their personality disorder and
received the antidepressants showed no improvement in their
mental state.
Discussion 
The total number of patients observed in this study is small,
as is also the case with other similar reports of patients of
major depressive illness secondary to INF administration
in HCV patients. These studies are not standardized and do
not take into account dose and duration of INF treatment.
Inevitably they also have heterogeneous patient populations,
and there is non-uniformity of the diagnostic criteria for
depression and the assessment methods employed.
In the six patients who developed significant depressive
illness, the complete therapeutic response to SSRI
antidepressant therapy in all of them is striking. Other
workers have also reported similar high success rates in the
treatment of depression following INF- therapy, with Turner
and Blackwell (2005) reporting effective response in up to
75% and Lang et al 78.5% (2003). Both Schramm et al
Table 1 IFN-induced MDD and treatment outcome
Age and sex Onset of MDD ADT ADT Outcome 1a Outcome 2b
(years) following IFN-α α α α α duration
therapy (months)
(weeks)
44 M 4 Paroxetine 40 mg 12/12 Full Yes
52 F 6 Paroxetine 40 mg 14/12 Full Yes
35 M 6 Citalopram 20 mg 10/12 Full Yes
55 F 6 Sertraline 50 mg 8/12 Full No, treatment
stopped due to
liver carcinoma
22 F 10 Sertraline 50 mg 3/12 Full No, dropped out
38 M 16 Sertraline 50 mg 2/12 Full Yes
aOutcome 1 = remission of MDD
bOutcome 2 = completion of antiviral treatment
Abbreviations: ADT, antidepressant treatment; INF,  interferon; MDD, major depressive disorder.Neuropsychiatric Disease and Treatment 2006:2(3) 357
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(2000) and Hauser (2004) also reported almost 100%
success in their series. This is in contrast to the treatment
outcome in randomized, controlled clinical trials in major
depression in the general population where the overall
efficacy for most old and new antidepressant treatments is
50%–55% (Parker 2005; Khan et al 2005). We would like
to take into account the statistical differences between very
small numbers of patients observed in this study with the
outcome of much larger clinical studies. Nonetheless,
differences in the reversibility of INF-induced depression
pending its further confirmation from larger standardized
studies is a significant clinical observation. This observation
warrants further discussion. If the pathophysiology of INF-
α is significantly reversible then there is cause to believe
that this pathophysiology differs from that of major
depression occurring in the general population. The role of
intrinsic cytokines may incorporate several other and more
complex pathways (Wichers and Maes 2002) in major
depressive disorder. For example, intrinsic cytokines are
potent modulators of corticotrophin-releasing hormone
(CRH) which produces heightened hypothalamic-pituitary-
adrenal (HPA) axis activity characterized by an increase in
adrenocorticotropic hormone and cortisol, both of which
have been reported to be elevated in major depressive illness
(Brebner et al 2000; Dunn 2001).
The role of the enzyme IDO has been implicated in the
pathophysiology of depression induced by INF-α in HCV
patients (Wichers et al 2005b). This enzyme is stimulated
by proinflammatory cytokines including INF-α (Wichers
et al 2005b). Its implications are as follows. First, the
stimulation of IDO activity induces the kynurenine pathway
resulting in the production of neurotoxic metabolites
(depressogenic event). Second, the tryptophan availability
to brain is decreased. In a prospective study of 16 patients
with hep C who were treated with INF-α, Wichers et al
(2005b) measured the onset and severity of depression,
tryptophan, and kynurenine ratio and its metabolic product
kynurenic acid ratio. They found that the Montgomery
Asberg Depression Rating Scale was significantly associated
over time with the kynurenine and kynurenic acid ratio,
reflecting increased IDO activity. The Wichers et al (2005b)
study favours the IDO switch pathway rather than the
serotonin depletion.
We speculate that one possible or an alternative
mechanism for the reversibility and complete remission of
symptoms in these patients may be explained by the down-
regulation/modification of the IDO stimulation/activity, with
SSRI antidepressants resulting in modulation of the
kynurenate and the quinolinate ratio. This speculation is
further supported by the observation that in our cohort,
the patients who received INF-α therapy and developed
aggravation of their personality disorder, showed no
improvement, as they possibly did not have the
underlying IDO pathophysiology and therefore INF-
induced depression.
Conclusion
The SSRIs have therapeutic efficacy in the treatment of INF-
α-induced major depression in HCV patients and may have
mechanism and sites of action other than conventionally
considered. Other implication of our observation are that
patients who are receiving treatment with pro-inflammatory
cytokines should be routinely screened for depressive
symptoms, as these symptoms appear to be fully responsive
to therapeutic intervention. Future clinical studies of
antidepressants should incorporate cellular and biochemical
response of the monocytes and lymphocytes in a variously
depressed population of patients. A consensus should be
developed as how to undertake larger multicenter studies to
examine the role of IDO, in the pathophysiology of
depression.
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